Dilated Cardiomyopathy Market Segmentation:
By Therapeutics
- Aldosterone antagonists
- Angiotensin-converting enzyme (ACE) Inhibitors
- Angiotensin II Receptor Blockers
- Beta-blockers
- Others
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
Frequently Asked Questions
The Dilated Cardiomyopathy market is estimated to be USD 4.8 billion in 2023.
Increasing prevalence, advancing diagnostics and treatment devices, emerging gene and stem cell therapies.
Low awareness, high treatment costs, stringent regulatory approvals.
Implantable cardiac devices like CRTs and ICDs.
Abbott Laboratories. Amgen, AstraZeneca, Bayer, Johnson & Johnson, Merck, Novartis, Pfizer, Sanofi, Teva Pharmaceuticals
The market is expected to grow at a CAGR of 6.6% from 2023-2030 to reach USD 7.5 billion.
Prevalence growth, device innovation, emerging therapies like gene and stem cell, remote monitoring.